Are vasodilators still indicated in the treatment of severe aortic regurgitation?
Aortic regurgitation (AR) is a valve disease that causes severe complications and reduces life expectancy. Surgical correction is required in the late stages of the disease. In less advanced forms, treatment with vasodilators is a consideration. The available evidence suggests that this type of treatment has a favorable effect on the consequences of AR, particularly left ventricular remodeling. However, the impact of vasodilators on clinical endpoints complicating the course of AR remains in doubt. The limited evidence supporting or opposing the utilization of vasodilators in AR hinders drawing firm conclusions and emphasizes the process of individualized interpretation of the clinical presentation of patients with the disease.
Inamo
Jocelyn
J
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Enriquez-Sarano
Maurice
M
D001022:Aortic Valve Insufficiency / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D001783:Blood Flow Velocity / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D006801:Humans; D012720:Severity of Illness Index; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000209:etiology / Q000517:prevention & control; D020257:Ventricular Remodeling / Q000187:drug effects
D014665:Vasodilator Agents